Articles & Whitepapers
The Challenge: One of the most common challenges in immuno-oncology is identifying the indications and patient populations that would benefit from a specific therapy, especially on top of Standard of Care (SOC) treatments. Our platform tackled this challenge of indication prioritization and patient stratification for a combination of a specific target (A) with an anti-PDX drug that one of our ...
The Challenge: With a drug in pre-clinical stage, our client was looking for the first indication to go into clinical ...
A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the ...
POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19
Neeuro (Singapore) and epihunter (Belgium) partner to create new and innovative digital solutions for people with brain disorders
Equipment & Solutions
ReadyCircuit jumper tube set with C-Flex ID tubing terminating with ReadyMate to SterilEnz TC connectors. Port tubing and ReadyMate single-use connectors are preconfigured into ReadyCircuits to connect with a variety of ReadyCircuit process components. Jumper assemblies are supplied gamma-irradiated with a certificate of quality. C-Flex jumpers enable tube sealing/fusing and this facilitates ...
A new version of HALO® and HALO AI are coming soon! In this half hour webinar, Donald Allen will discuss and demonstrate new features and functionalities in this software release and end with a Q/A session. This webinar will cover all of the features in the release while taking a deeper dive into multiplex workflows and membrane segmentation in HALO and HALO AI 3.6. Sign up for the upcoming ...